CN117122692B - Targeting nano-carrier and preparation method and application thereof - Google Patents
Targeting nano-carrier and preparation method and application thereof Download PDFInfo
- Publication number
- CN117122692B CN117122692B CN202311109923.6A CN202311109923A CN117122692B CN 117122692 B CN117122692 B CN 117122692B CN 202311109923 A CN202311109923 A CN 202311109923A CN 117122692 B CN117122692 B CN 117122692B
- Authority
- CN
- China
- Prior art keywords
- pamam
- nano
- sese
- solution
- bpnps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002539 nanocarrier Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 230000008685 targeting Effects 0.000 title claims abstract description 20
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 83
- 229920000962 poly(amidoamine) Polymers 0.000 claims abstract description 17
- 239000002135 nanosheet Substances 0.000 claims abstract description 11
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 37
- 239000000243 solution Substances 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 21
- 229960000304 folic acid Drugs 0.000 claims description 21
- 235000019152 folic acid Nutrition 0.000 claims description 21
- 239000011724 folic acid Substances 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 17
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 claims description 16
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 claims description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 claims description 16
- 229940055619 selenocysteine Drugs 0.000 claims description 16
- 235000016491 selenocysteine Nutrition 0.000 claims description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 230000035484 reaction time Effects 0.000 claims description 9
- 239000006185 dispersion Substances 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000002064 nanoplatelet Substances 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 229910052786 argon Inorganic materials 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000007872 degassing Methods 0.000 claims description 2
- 238000009210 therapy by ultrasound Methods 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 abstract description 22
- 208000014018 liver neoplasm Diseases 0.000 abstract description 22
- 108090000623 proteins and genes Proteins 0.000 abstract description 19
- 238000011282 treatment Methods 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 8
- 238000007626 photothermal therapy Methods 0.000 abstract description 8
- 239000002086 nanomaterial Substances 0.000 abstract description 7
- 210000004881 tumor cell Anatomy 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 5
- 238000001415 gene therapy Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 21
- 108020005198 Long Noncoding RNA Proteins 0.000 description 13
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 239000002105 nanoparticle Substances 0.000 description 9
- 230000003833 cell viability Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000004043 responsiveness Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010087230 Sincalide Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a targeting nano-carrier and a preparation method and application thereof, belonging to the technical field of biomedicine. The targeting nano-carrier comprises a black phosphorus nano-sheet and a modified PAMAM coated on the surface of the black phosphorus nano-sheet, wherein the modified PAMAM contains a diselenide bond and is modified with FA molecules. The targeting nano-carrier takes black phosphorus as a core framework and has a photo-thermal effect; secondly, the modified dendritic macromolecule PAMAM modifies the surface of the nano-material, so that the stability of the nano-material can be improved, and functional genes can be loaded; in addition, FA facilitates enrichment of nanomaterial in tumor cells. The nanometer material can be applied to medicines for treating liver cancer, or gene therapy and photothermal therapy, and provides a new idea for high-efficiency treatment of liver cancer.
Description
Technical Field
The invention relates to the technical field of biomedicine, in particular to a targeting nano-carrier and a preparation method and application thereof.
Background
Hepatocellular carcinoma (HCC) is one of the most common high mortality cancers worldwide. In recent years, the incidence of HCC worldwide has continuously increased, and is attracting more and more attention. The effective treatment of early liver cancer is operation, and the survival rate of the early liver cancer is 89-93% after 5 years of operation treatment. However, only a few HCC patients (about 20%) can be diagnosed early, most HCC patients (> 70%) are advanced, cannot be surgically resected, and can only be treated by other methods including liver transplantation, transcatheter Arterial Chemoembolization (TACE) and systemic chemotherapy. However, other treatment methods have limitations, so that the treatment effect of liver cancer is not ideal. Therefore, there is an urgent need to explore innovative therapeutic methods for liver cancer, and to remedy the deficiency of clinical treatment.
With the intensive research into long-chain non-coding rna (long-chain noncoding rna, lncRNAs), lncRNAs were found to play an important role in tumorigenesis, development, metastasis and apoptosis. Research on the role of lncRNAs in the occurrence and development of liver cancer is also possible to provide a new breakthrough for diagnosis and treatment of future liver cancer. At present, lncRNAs become important research hotspots in the field of tumor biology, but the research on the relationship between lncRNAs and tumors is still in the starting stage. CRNDE expression is significantly upregulated in most malignant tumors. CRNDE can participate in the biological process of related tumors by influencing epigenetic regulation and control of chromatin, expression of some important proteins, tumor specific signal paths and cell metabolism, so as to promote proliferation, migration and invasion of tumor cells, inhibit apoptosis and finally promote occurrence and development of tumors.
Currently, lncRNAs molecular technology has entered the experimental stage of human body, and is one of the most promising methods for treating various genetically mutated tumors. However, clinical use of lncRNAs remains a major challenge, such as instability in serum, susceptibility to nuclease degradation in the extracellular environment, electrostatic repulsion of negatively charged lncRNAs from negatively charged cell membranes, etc., which can severely affect transport and absorption of lncRNAs. Because of these characteristics, free lncRNAs are difficult to target directly to specific cells, and chemical modification of lncRNAs or loading of lncRNAs into protective carrier materials to improve stability of lncRNAs is one of the current research hotspots. Folic Acid (FA), a targeting motif that is widely studied, is a natural component that does not cause allergic reactions like many proteins. In addition, FA receptors are overexpressed in kidney, lung and breast cancer tissues, while expression levels are lower in normal tissues. Thus, FA functional nanoparticles can specifically enhance uptake of the composite pharmaceutical formulation by tumor cells via FA receptor-mediated endocytosis. Meanwhile, the FA-modified composite polymer nano-particles become potential carriers for tumor targeted drug delivery.
In recent years, phototherapy (photothermal therapy, PTT) has become a rapidly developing new cancer treatment. Compared with the traditional tumor ablation method, the PTT has higher local effect and can be used for the areas with higher surgical difficulty. Black Phosphorus (BP) is a novel inorganic material, is an allotrope of white phosphorus and red phosphorus, and is mainly applied to the fields of lithium ion batteries, storage devices and the like. In recent years, it has been found that a two-dimensional lamellar structure of BP can be obtained by a graphene-like mechanical exfoliation method, and exhibits unique optical properties. BP was first used for photothermal therapy in the biomedical field. BP can generate high heat under the irradiation of near infrared laser (808 nm), and can be used for realizing high-efficiency and safe tumor photothermal treatment. Compared with the traditional inorganic nano material, BP can be oxidatively degraded into safe and nontoxic small molecules such as phosphate, phosphite and the like under physiological conditions.
Disclosure of Invention
Based on the above, it is necessary to provide a targeting nanocarrier to achieve targeting of liver cancer and improve the therapeutic effect of liver cancer.
The technical scheme of the invention is as follows: the targeting nano-carrier comprises a black phosphorus nano-sheet and a modified PAMAM coated on the surface of the black phosphorus nano-sheet, wherein the modified PAMAM contains a diselenide bond and is modified with FA molecules.
The nano-carrier takes black phosphorus as a core skeleton, and the carrier can have rich positive charges by modifying a modified polymer PMMA, so that the carrier can increase the load energy of a negatively charged functional gene such as a gene shCRNDE; the diselenide bond has GSH responsiveness, and black phosphorus is coated by the modified polymer PAMAM with GSH responsiveness, so that degradation can be prevented, and the stability of the nano carrier is improved; meanwhile, FA is modified into a guide molecule targeting the FA receptor on the liver cancer cell, so that the enrichment of the nano material in the tumor cell is promoted, and the high-efficiency combined treatment of the liver cancer tumor cell can be realized.
In one embodiment, the particle size of the targeting nano-carrier is 200nm, the zeta potential is 18mV, and the targeting nano-carrier has a good effect of killing liver cancer cells after gene loading.
The invention also provides a preparation method of the targeting nano-carrier, which comprises the following steps: (1) preparing black phosphorus nano-sheet BPNPs: dispersing black phosphorus in pure water, stirring, degassing the solution by flowing argon, then carrying out ultrasonic treatment on the mixed solution under ice bath condition to obtain brown dispersion, centrifuging the brown dispersion, collecting supernatant and further centrifuging the collected supernatant to obtain black phosphorus nanoplatelets BPNPs.
(2) Preparing PAMAM-se-FA comprising:
2.1 Synthesis of NH 2 -PEG-se-NH 2: dissolving selenocysteine hydrochloride in water, adding EDC and NHS into selenocysteine hydrochloride solution, and stirring for reaction; then drop wise add to NH 2 Stirring and reacting in PEG-COOH solution at room temperature, dialyzing, and freeze-drying to obtain NH 2 -PEG-SeSe-NH 2 ;
2.2 dissolving FA in DMSO, adding EDC and NHS into the FA solution, stirring at room temperature, adding the mixture into the PAMAM solution dropwise, stirring at room temperature for reaction, dialyzing, and freeze-drying to obtain PAMAM-FA;
2.3 adding EDC and NHS to the PAMAM-FA solution in water, stirring at room temperature, and adding dropwise to NH 2 -PEG-SeSe-NH 2 Stirring and reacting in water solution at room temperature, dialyzing, and freeze-drying to obtain PAMAM-SeSe-FA;
(3) Preparation of BP@PAMAM-SeSe-FA
Preparing a BPNPs aqueous solution, adding PAMAM-SeSe-FA, mixing, performing ultrasonic and stirring reaction to obtain the BP@PAMAM-SeSe-FA nano-carrier, namely the targeting nano-carrier.
The preparation method comprises the steps of firstly preparing black phosphorus nano-sheet BPNPs by adopting a liquid phase dissolution method; then taking the polymer as a core framework, and modifying the polymer PMMA-SeSe-FA to obtain the nano carrier BP@PAMAM-SeSe-FA, wherein the preparation method is simple and easy to operate and is beneficial to popularization.
In one embodiment, in the step (1), the mass ratio of black phosphorus to pure water is 10-30: 20-80 parts; the ultrasonic time is 6-24 hours; the centrifugal speed of the brown dispersion is 500 rpm-1000 rpm; the collected supernatant was centrifuged at 2000rpm to 4000rpm. Preferably, the mass ratio of black phosphorus to pure water is 25:50; the ultrasonic time is 12 hours; the brown dispersion was centrifuged at 1000rpm; the collected supernatant was centrifuged at 3750rpm.
In one embodiment, in step 2.1, the mass ratio of the raw materials is selenocysteine hydrochloride: deionized water: EDC: NHS: NH (NH) 2- PEG-cooh=5 to 15:2 to 8: 5-25: 5-20: 5 to 50, the reaction time of EDC and NHS with selenocysteine hydrochloride is 1 to 6 hours, and the selenocysteine hydrochloride solution and NH 2 The reaction time of the PEG-COOH is 6 to 24 hours; in the step 2.2, the mass ratio of FA to PAMAM is 1-10: 30-70 parts; in step 2.3, PAMAM-FA and NH 2 -PEG-SeSe-NH 2 The mass ratio of (2) is 10-30: 5.
preferentially, in the step 2.1, the mass ratio of the raw materials is that selenocysteine hydrochloride: deionized water: EDC: NHS: NH (NH) 2 PEG-COOH = 10:6:15:12:30, the reaction time of EDC and NHS with selenocysteine hydrochloride is 4h; selenocysteine hydrochloride solution and NH 2 The reaction time of PEG-COOH was 24h; in the step 2.2, the mass ratio of FA to PAMAM is 5:50; in the step 2.3, PAMAM-FA and NH 2 -PEG-SeSe-NH 2 The mass ratio of (2) is 20:5.
in one embodiment, in step (3), the mass ratio of BP to PAMAM-se-FA is 0.1 to 0.5:5 to 15; the ultrasonic time is 10-40 min; the reaction time is 2-8 h.
Preferably, in the step (3), the mass ratio of BP to PAMAM-se-FA is 0.375:10; the ultrasonic time is 30min; the reaction time was 6h.
In one embodiment, step (1) further comprises resuspending the obtained BPNPs in PBS solution to obtain a BPNPs-PBS solution, which is then stored at 4 ℃.
In one embodiment, in the step (3), the preparation of the aqueous solution of BPNPs is obtained by centrifuging the solution of BPNPs-PBS, removing the supernatant and re-suspending in water. Preferably, the centrifugal speed is 4000 rpm-8000 rpm; further preferably, the centrifugal speed is 6000rpm.
In still another aspect, the invention further provides application of the nano-carrier in preparing medicines for treating liver cancer, or gene therapy and photothermal therapy.
Compared with the prior art, the invention has the following beneficial effects:
the nano-carrier takes black phosphorus as a core skeleton, and the modified polymer PMMA is modified, so that the carrier has rich positive charges, and the loading capacity of the carrier on negatively charged functional genes such as shCRNDE is improved; the diselenide bond has GSH responsiveness, and is coated by the modified polymer PAMAM responded by GSH, so that black phosphorus degradation can be prevented, and the stability of the nano carrier is improved; meanwhile, FA is modified into a guide molecule targeting the FA receptor on the liver cancer cell, so that the enrichment of the nano material in the tumor cell is promoted, and the high-efficiency combined treatment of the liver cancer can be realized. The preparation method of the invention firstly adopts a liquid phase dissolution method to prepare the black phosphorus nano-sheet BPNPs; then taking the polymer as a core framework, and modifying the polymer PMMA-SeSe-FA to obtain the nano carrier BP@PAMAM-SeSe-FA, wherein the preparation method is simple and easy to operate and is beneficial to popularization. The nano-carrier can be applied to preparation of medicines for treating liver cancer or gene therapy and photothermal therapy.
Drawings
FIG. 1 is a transmission electron microscope image of black phosphorus nanoplatelets BPNPs and a nanocarrier BP@PAMAM-SeSe-FA according to an embodiment of the invention;
FIG. 2 shows Zeta potential test results;
FIG. 3 shows cytotoxicity test results;
FIG. 4 is a photo-thermal profile of BP@PAMAM-SeSe-FA at various concentrations;
FIG. 5 shows the results of cell viability test.
Detailed Description
In order that the invention may be readily understood, a more complete description of the invention will be rendered by reference to the appended drawings. Preferred embodiments of the present invention are shown in the drawings. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. The term "and/or" as used herein includes any and all combinations of one or more of the associated listed items.
Definition:
BP: black phosphorus;
BPNPs: black phosphorus nanoplatelets;
EDC: 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride;
NHS: n-hydroxysuccinimide;
NH 2 -PEG-COOH: amino polyethylene glycol carboxyl group
PBS: phosphate buffer;
DMSO: dimethyl sulfoxide;
FA: folic acid;
PAMAM: polyamide-amine dendrimers.
The source is as follows:
the reagents used in the following examples, unless otherwise specified, are all commercially available; the methods used in the examples below, unless otherwise specified, are all conventional.
Example 1
(1) Preparation of black phosphorus nano-sheet BPNPs
BP 25mg was dissolved in 50ml of pure water, and vigorously stirred. The solution was degassed with flowing argon to eliminate dissolved oxygen molecules and reduce oxidation during stripping. Then, the mixed solution was sonicated in an ice bath at a power of 250W (45 s on, 15s off for a total time of 12 h). The brown dispersion obtained was centrifuged at 1000rpm for 10min, the bulk BP was removed, and the supernatant containing BPNPs was collected. The collected supernatant containing BPNPs was then centrifuged at 3750rpm at 4℃for 30min to remove water. The pure BPNPs obtained were resuspended in PBS to give a solution of BPNPs-BPS for further use and stored at 4 ℃.
(2) Preparation of PAMAM-SeSe-FA
2.1 Synthesis of NH 2- PEG-SeSe-NH 2 :10 mg of selenocysteine hydrochloride is dissolved in 6mL of water, 15mg of EDC and 12mg of NHS are added into the selenocysteine hydrochloride solution, and the mixture is stirred for reaction for 4h. And adding the selenocysteine hydrochloride solution dropwise to 15mL of NH 2 The reaction was stirred at room temperature overnight in the PEG-COOH solution. Dialyzing for 24 hours, and freeze-drying to obtain NH 2 -PEG-SeSe-NH 2 。
2.2 Synthesis of PAMAM-FA
5mg of FA is dissolved in DMSO, 10.2mg of EDC and 8.5mg of NHS are added into the FA solution, the mixture is stirred for 4 hours at room temperature, then the mixture is added into 10mL of 50mg of PAMAM solution dropwise, the mixture is stirred at room temperature for reaction overnight, dialysis is carried out for 24 hours, and the PAMAM-FA is obtained after freeze drying.
2.3 Synthesis of PAMAM-SeSe-FA
20mg of the PAMAM-FA solution synthesized in 2.2 was taken in water, 18mg of EDC and 16.5NHS were added to the PAMAM-FA solution, stirred at room temperature for 4 hours, and then added dropwise to NH 2 -PEG-SeSe-NH 2 In the aqueous solution, the reaction was stirred at room temperature overnight. Dialyzing for 24 hours, and freeze-drying to obtain PAMAM-SeSe-FA.
(3) Preparation of nano carrier BP@PAMAM-SeSe-FA
0.5mL of 750. Mu.g/mL BPPs-BPS solution was centrifuged at 6000rpm for 30min, and the supernatant was removed and resuspended in 2mL of water. 10mg of PAMAM-SeSe-FA was added thereto, followed by sonication for 30 minutes and stirring for reaction for 6 hours. After the reaction was completed, the mixture was centrifuged (6000 rpm,30 min) and resuspended in 2mL of water for further use.
Characterization and testing:
characterization of topography
Fig. 1 is a transmission electron microscope image of black phosphorus nanoplatelets BPNPs obtained in the step (1) and finally synthesized nano carriers bp@pamam-se-FA, and it can be seen from the image that each group of black phosphorus nanoplatelets have a lamellar structure, the particle size concentration is about 200nm, and the lamellar structure of black phosphorus is not affected by modification of polymers.
Zeta potential test
FIG. 2 shows the results of Zeta potential tests of synthesized BPNPs, PAMAM-SeSe-FA, BP@PAMAM-SeSe-FA, and BP@PAMAM-SeSe-FA/shCRNDE samples loaded with genes by uniformly mixing BP@PAMAM-SeSe-FA aqueous solution with the genes and then complexing for 0.5h at room temperature to obtain BP@PAMAM-SeSe-FA/shCRNDE complex; the result shows that the potential of the BPNPs is-15.3 mV, and the potential of the BP@PAMAM-SeSe-FA after the PAMAM-SeSe-FA is modified is +18mV; the positive charge of BP@PAMAM-SeSe-FA is slightly reduced compared with that of PAMAM-SeSe-FA, because black phosphorus is negatively charged, and PAMAM-SeSe-FA is positively charged, and electrostatic interaction is carried out to obtain BP@PAMAM-SeSe-FA, so that the positive charge of BP@PAMAM-SeSe-FA is slightly reduced, but the positive charge is still kept at about +18mV, and the potential of BP@PAMAM-SeSe-FA/shCRNDE is +13.4mV after the genes are loaded, so that the nano system can well load the genes.
Cytotoxicity of cells
The cytotoxicity of the nanocarrier BP@PAMAM-SeSe-FA on BEL-7402 cells was evaluated by using a method of detecting the cell activity with CCK-8. The specific operation steps are as follows: BEL-7402 cells were first seeded into 96-well plates at a density of 5000 cells/well, and then placed in a carbon dioxide incubator for culture adherence overnight. Subsequently, the original medium was aspirated and replaced with fresh complete medium containing BP@PAMAM-SeSe-FA at different concentrations, selected from the range of BP@PAMAM-SeSe-FA at 5-300. Mu.g/mL, 5 in parallel. The cells were then incubated in an incubator for 24h, washed once with PBS and 100. Mu.L of fresh medium (containing 10% CCK-8) was added to each well. Incubation in incubator for a period of time, and finally detection and recording of absorbance at 450nm wavelength using a microplate reader, cell viability was calculated by the following formula: cell viability (%) = (experimental group absorbance-blank group absorbance)/(negative control group absorbance-blank group absorbance) ×100%. As shown in FIG. 3, the cell viability of BEL-7402 cells was 102.5% at a BP@PAMAM-SeSe-FA nanoparticle concentration of 10. Mu.g/mL, and it was found that the low concentration of black phosphorus nanoparticles did not affect cell proliferation. In addition, with increasing concentration of black phosphorus nanoparticles, the survival rate of BEL-7402 cells was slightly decreased but still kept high, and when the concentration of BP@PAMAM-SeSe-FA nanoparticles was 100. Mu.g/mL, the survival rate of cells was 97.4% in turn. When the concentration of BP@PAMAM-SeSe-FA nanoparticles is as high as 300 mug/mL, the cell survival rate of cells is still more than 90%, and even though the black phosphorus nanoparticles are very high, the cytotoxicity is still very low, which indicates that the nano-carrier provided by the embodiment of the invention has lower cytotoxicity.
Photothermal properties
The resulting nanocarriers BP@PAMAM-SeSe-FA were dispersed in water to prepare solutions of different concentrations (40, 80, 160 and 320. Mu.g/mL). At room temperature, 1mL of the above solutions with different concentrations are respectively added into a cuvette, a thermocouple thermometer is inserted, and the power is 1.5W/cm 2 The liquid surface was irradiated with near infrared light of 808nm for 5min, and the temperature was recorded every 10 s. And (3) plotting by taking time as an abscissa and temperature as an ordinate, and comparing the in-vitro photo-thermal effects of materials with different concentrations. Meanwhile, deionized water is used as a control group and recorded by an infrared thermal imager. Fig. 4 shows time-temperature curves of materials at different concentrations. It can be seen from the graph that the higher the concentration, the more pronounced the temperature rise. At a material concentration of 50. Mu.g/mL, the temperature was raised to 48.3℃over 5 min. The nano-carrier of the embodiment of the invention has good photo-thermal performance.
Inhibition of cell proliferation in vitro
In order to explore cytotoxicity of the nano gene vector in the embodiment of the invention under the conditions of genes and light and heat, liver cancer cells BEL-7402 are selected, 5 groups of experimental controls are established, and the following nano particles are respectively added to each group of cells for co-culture: shCRNDE, BP@PAMAM-SeSe-FA, BP@PAMAM-SeSe-FA+NIR, BP@PAMAM-SeSe-FA/shCRNDE+NIR, BP@PAMAM-SeSe-FA/shCRNDE, wherein the preparation of the loaded gene sample is as described above, followed by PBS set as control, wherein NIR stands for treatment with 808nm NIR near infrared laser irradiation, laser power density is 1.5W/cm 2 The illumination time was 5min, and the gene amount per well was 0.5. Mu.g. After the cells of each group are co-cultured for 24 hours under the same condition, the cell activity is detected by using a CCK-8 method cell proliferation detection kit. The results are shown in FIG. 5, in which 1.PBS,2.shCRNDE,3.BP@PAMAM-SeSe-FA,4.BP@PAMAM-SeSe-FA+NIR,5.BP@PAMAM-SeSe-FA/shCRNDE,6.BP@PAMAM-SeSe-FA/shCRNDE+NIR。
The result shows that the cell viability of the single material BP@PAMAM-SeSe-FA is not obviously different from that of the PBS group, the cell viability of the BP@PAMAM-SeSe-FA+NIR group is 65.3%, the cell viability of the BP@PAMAM-SeSe-FA/shCRNDE group is 50.9%, and the cell viability of the BP@PAMAM-SeSe-FA/shCRNDE+NIR group is 20.9%, so that the nano-carrier can kill liver cancer cells more only by combining genes with light and heat.
In conclusion, the targeting nano-carrier provided by the invention takes black phosphorus as a core skeleton, and has a photo-thermal effect due to the excellent optical property; the modified polymer PMMA is modified by coating, so that the carrier has rich positive charges, and the capability of carrying negatively charged functional genes such as shCRNDE genes is improved; the diselenide bond has GSH responsiveness, so that the modified polymer PAMAM with GSH responsiveness is coated, thereby preventing black phosphorus from degradation and improving the stability of the carrier; meanwhile, FA is modified into a guide molecule targeting the FA receptor on the liver cancer cell, so that enrichment of the nano material in tumor cells is promoted. When the nano-carrier is applied, the combination of gene and photothermal therapy can be realized, so that the high-efficiency combined treatment of liver cancer is realized, and a new idea is provided for the high-efficiency treatment of liver cancer.
The technical features of the above-described embodiments may be arbitrarily combined, and all possible combinations of the technical features in the above-described embodiments are not described for brevity of description, however, as long as there is no contradiction between the combinations of the technical features, they should be considered as the scope of the description.
The above examples illustrate only a few embodiments of the invention, which are described in detail and are not to be construed as limiting the scope of the invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention. Accordingly, the scope of protection of the present invention is to be determined by the appended claims.
Claims (7)
1. The preparation method of the targeting nano-carrier comprises a black phosphorus nano-sheet and a modified PAMAM coated on the surface of the black phosphorus nano-sheet, wherein the modified PAMAM contains a diselenide bond and is modified with FA folic acid molecules; the particle size of the nano carrier is 200nm, and the Zeta potential is 18mV; the preparation method is characterized by comprising the following steps:
(1) Preparing black phosphorus nano-sheet BPNPs: dispersing black phosphorus in pure water, stirring, degassing by flowing argon, then carrying out ultrasonic treatment on the solution under ice bath conditions to obtain brown dispersion, centrifuging the brown dispersion, collecting supernatant and further centrifuging the collected supernatant to obtain black phosphorus nanoplatelets BPNPs;
(2) Preparing PAMAM-se-FA comprising:
2.1 Synthesis of NH 2 -PEG-SeSe-NH 2 : dissolving selenocysteine hydrochloride in water, adding EDC and NHS into selenocysteine hydrochloride solution, and stirring for reaction; then drop wise add to NH 2 Stirring and reacting in PEG-COOH solution at room temperature, dialyzing, and freeze-drying to obtain NH 2 -PEG-SeSe-NH 2 ;
2.2 Dissolving FA in DMSO, adding EDC and NHS into the FA solution, stirring at room temperature, adding the mixture dropwise into the PAMAM solution, stirring at room temperature for reaction, dialyzing, and lyophilizing to obtain PAMAM-FA;
2.3 adding EDC and NHS to the PAMAM-FA solution in water, stirring at room temperature, and adding dropwise to NH 2 -PEG-SeSe-NH 2 Stirring and reacting in water solution at room temperature, dialyzing, and freeze-drying to obtain PAMAM-SeSe-FA;
(3) Preparation BP@ PAMAM-SeSe-FA:
preparing a BPNPs aqueous solution, adding PAMAM-SeSe-FA for mixing, and performing ultrasonic and stirring reaction to obtain the BP@ PAMAM-SeSe-FA nano-carrier, namely the targeting nano-carrier.
2. The preparation method according to claim 1, wherein the mass-volume ratio of black phosphorus to pure water in the step (1) is 10-30 mg: 20-80 ml; the ultrasonic time is 6 h-24 h; the centrifugal speed of the brown dispersion is 500 rpm-1000 rpm; the collected supernatant has a centrifugal speed of 2000rpm to 4000rpm.
3. The method according to claim 1, wherein,
in the step 2.1, the raw material ratio is selenocysteine hydrochloride: deionized water: EDC: NHS: NH (NH) 2 -PEG-COOH = 5-15 mg: 2-8 ml: 5-25 mg: 5-20 mg: 5-50 ml; the reaction time of EDC and NHS with selenocysteine hydrochloride is 1-6 h; selenocysteine hydrochloride solution and NH 2 The reaction time of PEG-COOH is 6-24 h;
in the step 2.2, the mass ratio of FA to PAMAM is 1-10: 30-70 parts.
4. The method according to claim 1, wherein in the step (3), the mass ratio of BPNPs to PAMAM-se-FA is 0.1 to 0.5:5 to 15; the ultrasonic time is 10-40 min; the reaction time is 2-8 h.
5. The method of claim 1, wherein step (1) further comprises re-suspending the obtained BPNPs in a PBS solution to obtain a BPNPs-PBS solution, and then storing at 4 ℃.
6. The method according to claim 5, wherein in the step (3), the preparation of the aqueous solution of BPNPs is carried out by centrifuging the solution of BPNPs-PBS, removing the supernatant and then re-suspending in water.
7. The method according to claim 6, wherein the centrifugal speed is 4000rpm to 8000 rpm.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311109923.6A CN117122692B (en) | 2023-08-30 | 2023-08-30 | Targeting nano-carrier and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311109923.6A CN117122692B (en) | 2023-08-30 | 2023-08-30 | Targeting nano-carrier and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117122692A CN117122692A (en) | 2023-11-28 |
CN117122692B true CN117122692B (en) | 2024-04-05 |
Family
ID=88859565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311109923.6A Active CN117122692B (en) | 2023-08-30 | 2023-08-30 | Targeting nano-carrier and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117122692B (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106496585A (en) * | 2016-10-21 | 2017-03-15 | 浙江大学 | Sensitive graphene oxide based nano-materials of a kind of ROS and its preparation method and application |
CN107496444A (en) * | 2017-08-29 | 2017-12-22 | 深圳大学 | A kind of selenium doping black phosphorus prodrug and preparation method thereof |
WO2018095017A1 (en) * | 2016-11-25 | 2018-05-31 | 深圳大学 | Targeted photothermal black phosphorus nano preparation and preparation method and application thereof |
KR20200087505A (en) * | 2019-01-11 | 2020-07-21 | 영남대학교 산학협력단 | Drug Carrier using Black Phosphorus Nanosheet |
CN112870370A (en) * | 2021-03-05 | 2021-06-01 | 广州贝奥吉因生物科技股份有限公司 | Targeting drug-loading system based on black phosphorus nanosheet and preparation method thereof |
-
2023
- 2023-08-30 CN CN202311109923.6A patent/CN117122692B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106496585A (en) * | 2016-10-21 | 2017-03-15 | 浙江大学 | Sensitive graphene oxide based nano-materials of a kind of ROS and its preparation method and application |
WO2018095017A1 (en) * | 2016-11-25 | 2018-05-31 | 深圳大学 | Targeted photothermal black phosphorus nano preparation and preparation method and application thereof |
CN107496444A (en) * | 2017-08-29 | 2017-12-22 | 深圳大学 | A kind of selenium doping black phosphorus prodrug and preparation method thereof |
KR20200087505A (en) * | 2019-01-11 | 2020-07-21 | 영남대학교 산학협력단 | Drug Carrier using Black Phosphorus Nanosheet |
CN112870370A (en) * | 2021-03-05 | 2021-06-01 | 广州贝奥吉因生物科技股份有限公司 | Targeting drug-loading system based on black phosphorus nanosheet and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
Black phosphorus nanosheets-based platform for targeted chemo-photothermal synergistic cancer therapy;Feifei Peng et al.;《Colloids and Surfaces B: Biointerfaces》(第198期);111467 * |
Black phosphorus nanosheets-based platform for targeted chemo-photothermal synergistic cancer therapy;Peng Feifei et al.;《Colloids and Surfaces B:Biointerfaces》;20201112(第198期);111467 * |
Also Published As
Publication number | Publication date |
---|---|
CN117122692A (en) | 2023-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhu et al. | Ru@ CeO2 yolk shell nanozymes: Oxygen supply in situ enhanced dual chemotherapy combined with photothermal therapy for orthotopic/subcutaneous colorectal cancer | |
Gulzar et al. | Nano-graphene oxide-UCNP-Ce6 covalently constructed nanocomposites for NIR-mediated bioimaging and PTT/PDT combinatorial therapy | |
Min et al. | A graphdiyne oxide‐based iron sponge with photothermally enhanced tumor‐specific Fenton chemistry | |
Zhang et al. | Fabrication of ZnPc/protein nanohorns for double photodynamic and hyperthermic cancer phototherapy | |
WO2018095017A1 (en) | Targeted photothermal black phosphorus nano preparation and preparation method and application thereof | |
Li et al. | A degradable hydrogel formed by dendrimer-encapsulated platinum nanoparticles and oxidized dextran for repeated photothermal cancer therapy | |
Wang et al. | MnO2-DNAzyme-photosensitizer nanocomposite with AIE characteristic for cell imaging and photodynamic-gene therapy | |
CN110623939B (en) | Preparation method of cantharidin-loaded tumor cell membrane encapsulated tellurium elementary substance nanoparticles | |
Gao et al. | AuNRs@ MIL-101-based stimuli-responsive nanoplatform with supramolecular gates for image-guided chemo-photothermal therapy | |
Wang et al. | Dextran coated Fe3O4 nanoparticles as a near-infrared laser-driven photothermal agent for efficient ablation of cancer cells in vitro and in vivo | |
He et al. | Ultra-dispersed biomimetic nanoplatform fabricated by controlled etching agglomerated MnO2 for enhanced photodynamic therapy and immune activation | |
CN114073767B (en) | Targeting response type therapeutic nanoparticle as well as preparation method and application thereof | |
CN110960697A (en) | Preparation method of zwitterion-modified dendrimer-coated copper sulfide nanoparticle/pDNA (deoxyribonucleic acid) compound | |
Chen et al. | Glucose oxidase-loaded colloidal stable WS2 nanobowls for combined starvation/photothermal therapy of colorectal tumors | |
Li et al. | Ultrasmall graphene oxide for combination of enhanced chemotherapy and photothermal therapy of breast cancer | |
Liu et al. | An all-in-one nanoplatform with near-infrared light promoted on-demand oxygen release and deep intratumoral penetration for synergistic photothermal/photodynamic therapy | |
Qian et al. | In situ injectable thermoresponsive nanocomposite hydrogel based on hydroxypropyl chitosan for precise synergistic calcium-overload, photodynamic and photothermal tumor therapy | |
CN117122692B (en) | Targeting nano-carrier and preparation method and application thereof | |
Fan et al. | Biomimetic piezoelectric nanomaterial-modified oral microrobots for targeted catalytic and immunotherapy of colorectal cancer | |
CN112516308B (en) | Near-infrared II-region laser controlled-release drug nano-liposome and preparation method and application thereof | |
CN110898221A (en) | Hollow mesoporous copper sulfide nano-particles, preparation method, application and pharmaceutical composition thereof | |
CN114887061B (en) | Preparation method and application of tumor-targeted photothermal gene combined therapy nano system | |
CN107625744B (en) | Core-shell structure nanocapsule and preparation method and application thereof | |
CN107096040B (en) | Gene-photothermal combined nanoparticle and preparation method and application thereof | |
Bai et al. | Blood cellular membrane-coated Au/polydopamine nanoparticle-targeted NIR-II antibacterial therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |